HK1198517A1 - Polyoma virus jc peptides and proteins in vaccination and diagnostic applications - Google Patents
Polyoma virus jc peptides and proteins in vaccination and diagnostic applications Download PDFInfo
- Publication number
- HK1198517A1 HK1198517A1 HK14112523.5A HK14112523A HK1198517A1 HK 1198517 A1 HK1198517 A1 HK 1198517A1 HK 14112523 A HK14112523 A HK 14112523A HK 1198517 A1 HK1198517 A1 HK 1198517A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pml
- vaccination
- polyoma virus
- peptides
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11006031A EP2548567A1 (en) | 2011-07-22 | 2011-07-22 | Polyoma virus JC peptides and proteins in vaccination and diagnostic applications |
| EP11006031 | 2011-07-22 | ||
| PCT/EP2012/064445 WO2013014134A2 (en) | 2011-07-22 | 2012-07-23 | Polyoma virus jc peptides and proteins in vaccination and diagnostic applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1198517A1 true HK1198517A1 (en) | 2015-05-15 |
Family
ID=46548481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14112523.5A HK1198517A1 (en) | 2011-07-22 | 2012-07-23 | Polyoma virus jc peptides and proteins in vaccination and diagnostic applications |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9738690B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2548567A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014520877A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140062702A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103826653A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012288955B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014001516A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2842543A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201490322A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1198517A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2014000776A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013014134A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150065367A1 (en) * | 2011-12-12 | 2015-03-05 | Janssen Diagnostics Bvba | Polyomavirus peptide sequences |
| US10300116B2 (en) | 2013-06-10 | 2019-05-28 | Ansun Biopharma, Inc. | Treatment for BK polyomavirus infection |
| US9931393B2 (en) | 2013-12-20 | 2018-04-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogenic JC polyomavirus compositions and methods of use |
| EP2926831A1 (en) * | 2014-03-31 | 2015-10-07 | Ruprecht-Karls-Universität Heidelberg | CD8+ T-cell epitopes from polyomavirus capsid protein VP1 for vaccination |
| WO2016073595A1 (en) * | 2014-11-05 | 2016-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | T cells and dendritic cells for polyomavirus therapy |
| WO2016104046A1 (ja) * | 2014-12-22 | 2016-06-30 | 日東電工株式会社 | 透明導電性フィルム |
| IT201600083859A1 (it) * | 2016-08-09 | 2018-02-09 | Univ Degli Studi Di Ferrara | Immunosaggio per l’identificazione di anticorpi contro il virus Polioma JC (JCPyV) mediante l’uso di peptidi sintetici. |
| CN113278634B (zh) | 2020-11-16 | 2022-06-28 | 艾棣维欣(苏州)生物制药有限公司 | 一种预防和治疗默克尔细胞癌的新型疫苗 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3767755B2 (ja) | 1995-06-23 | 2006-04-19 | エーザイ株式会社 | 抗jcウイルス抗体 |
| DE19543553B4 (de) | 1995-11-22 | 2009-04-09 | Deutsches Primatenzentrum Gmbh | VP-Antigene des JC-Virus |
| DE10131145B4 (de) | 2001-06-28 | 2005-07-14 | Innovent E.V. | Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen |
| JP4840792B2 (ja) | 2001-11-22 | 2011-12-21 | 独立行政法人科学技術振興機構 | JCウイルスagnoを対象としたPMLの治療 |
| AU2003238008A1 (en) | 2002-06-12 | 2003-12-31 | Temple University Of The Commonwealth System Of Higher Education | Method of cell growth inhibition with agnoprotein |
| JP2005341864A (ja) | 2004-06-02 | 2005-12-15 | Japan Science & Technology Agency | Jcウイルスの粒子形成阻害剤 |
| US7468186B2 (en) * | 2005-07-22 | 2008-12-23 | City Of Hope | Polyomavirus cellular epitopes and uses therefor |
| US20080057079A1 (en) | 2006-08-31 | 2008-03-06 | Baylor Research Institute | JC Virus Vaccine |
| CN100595765C (zh) * | 2008-06-30 | 2010-03-24 | 腾讯科技(深圳)有限公司 | 基于媒体播放器的关键词内容发布方法及系统 |
| AU2010210979B2 (en) * | 2009-02-05 | 2015-12-10 | Biogen Ma Inc. | Methods for the detection of JC polyoma virus |
| WO2010099205A1 (en) | 2009-02-24 | 2010-09-02 | The Trustees Of The University Of Pennsylvania | Methods for treating progressive multifocal leukoencephalopathy (pml) |
| EP2226392A1 (en) * | 2009-03-03 | 2010-09-08 | Assistance Publique - Hôpitaux de Paris | Method for detecting JCV infection |
| WO2011124652A1 (en) * | 2010-04-08 | 2011-10-13 | Fondazione Centro San Raffaele Del Monte Tabor | Immunodominant peptide of polyomavirus jc and uses thereof |
-
2011
- 2011-07-22 EP EP11006031A patent/EP2548567A1/en not_active Withdrawn
-
2012
- 2012-07-23 EP EP12737822.2A patent/EP2734218A2/en not_active Withdrawn
- 2012-07-23 EA EA201490322A patent/EA201490322A1/ru unknown
- 2012-07-23 KR KR1020147004608A patent/KR20140062702A/ko not_active Withdrawn
- 2012-07-23 US US14/234,065 patent/US9738690B2/en not_active Expired - Fee Related
- 2012-07-23 WO PCT/EP2012/064445 patent/WO2013014134A2/en not_active Ceased
- 2012-07-23 JP JP2014520691A patent/JP2014520877A/ja active Pending
- 2012-07-23 MX MX2014000776A patent/MX2014000776A/es unknown
- 2012-07-23 HK HK14112523.5A patent/HK1198517A1/xx unknown
- 2012-07-23 CN CN201280041815.3A patent/CN103826653A/zh active Pending
- 2012-07-23 AU AU2012288955A patent/AU2012288955B2/en not_active Expired - Fee Related
- 2012-07-23 CA CA2842543A patent/CA2842543A1/en not_active Abandoned
- 2012-07-23 BR BR112014001516A patent/BR112014001516A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US9738690B2 (en) | 2017-08-22 |
| MX2014000776A (es) | 2014-11-26 |
| CN103826653A (zh) | 2014-05-28 |
| CA2842543A1 (en) | 2013-01-31 |
| KR20140062702A (ko) | 2014-05-26 |
| AU2012288955B2 (en) | 2017-06-08 |
| WO2013014134A2 (en) | 2013-01-31 |
| WO2013014134A3 (en) | 2013-05-02 |
| JP2014520877A (ja) | 2014-08-25 |
| BR112014001516A2 (pt) | 2017-02-14 |
| AU2012288955A1 (en) | 2014-02-20 |
| EP2548567A1 (en) | 2013-01-23 |
| EP2734218A2 (en) | 2014-05-28 |
| NZ620196A (en) | 2016-10-28 |
| US20140356320A1 (en) | 2014-12-04 |
| EA201490322A1 (ru) | 2014-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013014134A3 (en) | Polyoma virus jc peptides and proteins in vaccination and diagnostic applications | |
| WO2012069568A3 (en) | Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination | |
| IN2014DN10288A (cg-RX-API-DMAC7.html) | ||
| WO2014113490A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| DK2280721T3 (da) | Indoleamin-2, 3-dioxygenasebaseret immunterapi | |
| BR112013032251A2 (pt) | composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina | |
| WO2013106834A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| EP3266464A3 (en) | Yeast-based therapeutic for chronic hepatitis b infection | |
| TR201800669T4 (tr) | Alzheimer hastaliğinda tau-aracili patoloji̇ni̇n tanilanmasi ve protei̇n bazli tedavi̇si̇ | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| MX346475B (es) | Peptidos inmunogenicos monomericos y multimericos. | |
| JP2016040284A5 (cg-RX-API-DMAC7.html) | ||
| MX391136B (es) | FRAGMENTOS DE OspA ESTABILIZADOS CON CISTEÍNA Y MÉTODO DE USO | |
| WO2011103567A3 (en) | Peptides and methods for inducing cell death | |
| WO2014160747A3 (en) | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection | |
| Morales et al. | HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1 | |
| MX356745B (es) | Anticuerpo monoclonal humano contra la proteina vp1 del virus jc. | |
| PH12015502844A1 (en) | Mammalian milk osteopontin for enhancing immune responsiveness | |
| WO2013006050A9 (en) | Peptides inducing or enhancing an immune response against prostate-specific membrane protein (psma) | |
| WO2016081869A3 (en) | Peptides for use in treatment and diagnosis of type 1 diabetes | |
| WO2016090022A8 (en) | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal | |
| WO2014165866A3 (en) | Methods for immune-based diagnosis, prevention and personalized treatment of narcolepsy | |
| WO2014053110A3 (de) | Peptide zur behandlung und frühdiagnose von morbus alzheimer und anderer tauopathien | |
| WO2015070207A3 (en) | Ama-1 epitopes, antibodies, compositions, and methods of making and using the same | |
| WO2015168607A3 (en) | Ceacam5 peptides for crohn's disease |